HUE031764T2 - Tetrahydropyrrolothiazine derivatives as BACE inhibitors - Google Patents
Tetrahydropyrrolothiazine derivatives as BACE inhibitors Download PDFInfo
- Publication number
- HUE031764T2 HUE031764T2 HUE13785730A HUE13785730A HUE031764T2 HU E031764 T2 HUE031764 T2 HU E031764T2 HU E13785730 A HUE13785730 A HU E13785730A HU E13785730 A HUE13785730 A HU E13785730A HU E031764 T2 HUE031764 T2 HU E031764T2
- Authority
- HU
- Hungary
- Prior art keywords
- mmol
- compound
- give
- solution
- added
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title claims description 8
- NDYYBQHNPPJCSU-UHFFFAOYSA-N 2,3,4,4a-tetrahydropyrrolo[2,3-e]thiazine Chemical class S1NCCC2N=CC=C21 NDYYBQHNPPJCSU-UHFFFAOYSA-N 0.000 title description 2
- 101150058765 BACE1 gene Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 165
- 229910052731 fluorine Inorganic materials 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- VOQPQBGCWBEYEV-AWEZNQCLSA-N (S)-1-(4-bromoacetamidobenzyl)EDTA Chemical compound OC(=O)CN(CC(O)=O)C[C@@H](N(CC(O)=O)CC(O)=O)CC1=CC=C(NC(=O)CBr)C=C1 VOQPQBGCWBEYEV-AWEZNQCLSA-N 0.000 claims 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 1
- 239000005977 Ethylene Substances 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 230000000399 orthopedic effect Effects 0.000 claims 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 162
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 152
- 239000000243 solution Substances 0.000 description 86
- 238000002360 preparation method Methods 0.000 description 64
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 56
- 238000006243 chemical reaction Methods 0.000 description 52
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 45
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 44
- 238000000034 method Methods 0.000 description 44
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 39
- 239000000203 mixture Substances 0.000 description 39
- 150000003839 salts Chemical class 0.000 description 37
- 230000002829 reductive effect Effects 0.000 description 36
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 32
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 31
- 238000010898 silica gel chromatography Methods 0.000 description 31
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 30
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 30
- 229960000510 ammonia Drugs 0.000 description 28
- 229910021529 ammonia Inorganic materials 0.000 description 28
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 27
- 101000894895 Homo sapiens Beta-secretase 1 Proteins 0.000 description 23
- 239000002904 solvent Substances 0.000 description 23
- 238000011282 treatment Methods 0.000 description 21
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 20
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 19
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 19
- 230000000694 effects Effects 0.000 description 19
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 18
- 208000024827 Alzheimer disease Diseases 0.000 description 18
- 102100021257 Beta-secretase 1 Human genes 0.000 description 17
- 108090000765 processed proteins & peptides Proteins 0.000 description 17
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 16
- 229910052757 nitrogen Inorganic materials 0.000 description 16
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 15
- 235000019341 magnesium sulphate Nutrition 0.000 description 15
- 238000004808 supercritical fluid chromatography Methods 0.000 description 15
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 14
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 14
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 14
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 14
- 230000005764 inhibitory process Effects 0.000 description 14
- 239000003480 eluent Substances 0.000 description 13
- 239000010410 layer Substances 0.000 description 13
- GNVRJGIVDSQCOP-UHFFFAOYSA-N n-ethyl-n-methylethanamine Chemical compound CCN(C)CC GNVRJGIVDSQCOP-UHFFFAOYSA-N 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 238000005160 1H NMR spectroscopy Methods 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 229920006395 saturated elastomer Polymers 0.000 description 12
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 11
- 239000000470 constituent Substances 0.000 description 11
- 239000012043 crude product Substances 0.000 description 11
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- -1 racemates Chemical class 0.000 description 11
- 239000011541 reaction mixture Substances 0.000 description 11
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 10
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
- 239000008346 aqueous phase Substances 0.000 description 10
- 238000003556 assay Methods 0.000 description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 10
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 10
- 239000012044 organic layer Substances 0.000 description 10
- 239000012071 phase Substances 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- IKIJFJKFIYFTBZ-BTDLBPIBSA-N 2-[2-[(4ar,7ar)-2-amino-7a-pyrazin-2-yl-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-6-yl]-5-fluoropyrimidin-4-yl]propan-2-ol Chemical compound C1=C(F)C(C(C)(O)C)=NC(N2C[C@@]3(N=C(N)SC[C@@H]3C2)C=2N=CC=NC=2)=N1 IKIJFJKFIYFTBZ-BTDLBPIBSA-N 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 9
- 229940086542 triethylamine Drugs 0.000 description 9
- VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical compound NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 description 8
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 8
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 8
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 8
- 125000002619 bicyclic group Chemical group 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 150000002923 oximes Chemical class 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 7
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 7
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 150000001408 amides Chemical class 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 7
- 208000010877 cognitive disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 208000027061 mild cognitive impairment Diseases 0.000 description 7
- 239000012074 organic phase Substances 0.000 description 7
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 7
- 229910052938 sodium sulfate Inorganic materials 0.000 description 7
- 235000011152 sodium sulphate Nutrition 0.000 description 7
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 6
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 6
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 238000005342 ion exchange Methods 0.000 description 6
- 150000002576 ketones Chemical class 0.000 description 6
- IUYHWZFSGMZEOG-UHFFFAOYSA-M magnesium;propane;chloride Chemical compound [Mg+2].[Cl-].C[CH-]C IUYHWZFSGMZEOG-UHFFFAOYSA-M 0.000 description 6
- 150000007530 organic bases Chemical class 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- JMXKSZRRTHPKDL-UHFFFAOYSA-N titanium ethoxide Chemical compound [Ti+4].CC[O-].CC[O-].CC[O-].CC[O-] JMXKSZRRTHPKDL-UHFFFAOYSA-N 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- AGIJRRREJXSQJR-UHFFFAOYSA-N 2h-thiazine Chemical compound N1SC=CC=C1 AGIJRRREJXSQJR-UHFFFAOYSA-N 0.000 description 5
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 5
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 239000003636 conditioned culture medium Substances 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 102000044297 human BACE1 Human genes 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 238000003118 sandwich ELISA Methods 0.000 description 5
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 4
- GQIRIWDEZSKOCN-UHFFFAOYSA-N 1-chloro-n,n,2-trimethylprop-1-en-1-amine Chemical compound CN(C)C(Cl)=C(C)C GQIRIWDEZSKOCN-UHFFFAOYSA-N 0.000 description 4
- RPYSVUUANIFTAP-UHFFFAOYSA-N 2-(2-chloro-5-fluoropyrimidin-4-yl)propan-2-ol Chemical compound CC(C)(O)C1=NC(Cl)=NC=C1F RPYSVUUANIFTAP-UHFFFAOYSA-N 0.000 description 4
- WDTSYONULAZKIE-UHFFFAOYSA-N 2-bromo-1-pyridin-3-ylethanone;hydron;bromide Chemical compound [Br-].BrCC(=O)C1=CC=C[NH+]=C1 WDTSYONULAZKIE-UHFFFAOYSA-N 0.000 description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 4
- CPEKAXYCDKETEN-UHFFFAOYSA-N benzoyl isothiocyanate Chemical compound S=C=NC(=O)C1=CC=CC=C1 CPEKAXYCDKETEN-UHFFFAOYSA-N 0.000 description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- BELYXJBTRGEAJY-UHFFFAOYSA-N tert-butyl n-(2-oxo-2-pyridin-3-ylethyl)-n-prop-2-enylcarbamate Chemical compound CC(C)(C)OC(=O)N(CC=C)CC(=O)C1=CC=CN=C1 BELYXJBTRGEAJY-UHFFFAOYSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 3
- IJOIGOJNSAMUQL-UHFFFAOYSA-N 1-(2-chloro-5-fluoropyrimidin-4-yl)ethanone Chemical compound CC(=O)C1=NC(Cl)=NC=C1F IJOIGOJNSAMUQL-UHFFFAOYSA-N 0.000 description 3
- ZYDUSFLGWDCFHO-UHFFFAOYSA-N 1-[(4-methoxyphenyl)methyl]-6a-pyridin-3-yl-3a,4,5,6-tetrahydro-3h-pyrrolo[3,4-c][1,2]oxazole Chemical compound C1=CC(OC)=CC=C1CN1C2(C=3C=NC=CC=3)CNCC2CO1 ZYDUSFLGWDCFHO-UHFFFAOYSA-N 0.000 description 3
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical compound CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 3
- HCQXULRWEPVBHP-UHFFFAOYSA-N 2-[bis(prop-2-enyl)amino]-1-pyridin-3-ylethanone Chemical compound C=CCN(CC=C)CC(=O)C1=CC=CN=C1 HCQXULRWEPVBHP-UHFFFAOYSA-N 0.000 description 3
- RWISDMQZKZXBIK-UHFFFAOYSA-N 2-chloro-5-fluoro-4-methoxy-6-methylpyrimidine Chemical compound COC1=NC(Cl)=NC(C)=C1F RWISDMQZKZXBIK-UHFFFAOYSA-N 0.000 description 3
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 3
- JMCXPYQZLBCIAB-UHFFFAOYSA-N 5-prop-2-enyl-6a-pyridin-3-yl-3,3a,4,6-tetrahydro-1h-pyrrolo[3,4-c][1,2]oxazole Chemical compound C1N(CC=C)CC2CONC21C1=CC=CN=C1 JMCXPYQZLBCIAB-UHFFFAOYSA-N 0.000 description 3
- BTDOCELRFCOJIJ-UHFFFAOYSA-N 6-(5-fluoropyrimidin-2-yl)-7a-pyridin-3-yl-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-2-amine Chemical compound C1C2CSC(N)=NC2(C=2C=NC=CC=2)CN1C1=NC=C(F)C=N1 BTDOCELRFCOJIJ-UHFFFAOYSA-N 0.000 description 3
- ZGORXVQABSGHNX-UHFFFAOYSA-N 6a-pyrazin-2-yl-1,3,3a,4,5,6-hexahydropyrrolo[3,4-c][1,2]oxazole Chemical compound N1OCC2CNCC21C1=CN=CC=N1 ZGORXVQABSGHNX-UHFFFAOYSA-N 0.000 description 3
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 3
- 239000005909 Kieselgur Substances 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 3
- ANHULAGGABEQRN-UHFFFAOYSA-N [4-amino-1-(5-fluoro-4-methoxy-6-methylpyrimidin-2-yl)-4-pyrazin-2-ylpyrrolidin-3-yl]methanol Chemical compound CC1=C(F)C(OC)=NC(N2CC(N)(C(CO)C2)C=2N=CC=NC=2)=N1 ANHULAGGABEQRN-UHFFFAOYSA-N 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 239000013058 crude material Substances 0.000 description 3
- 238000003821 enantio-separation Methods 0.000 description 3
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 3
- 125000000842 isoxazolyl group Chemical group 0.000 description 3
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 3
- SHWYUSFDCSHNJF-UHFFFAOYSA-N n-[(4-methoxyphenyl)methyl]hydroxylamine;hydrochloride Chemical compound Cl.COC1=CC=C(CNO)C=C1 SHWYUSFDCSHNJF-UHFFFAOYSA-N 0.000 description 3
- ACXSUNGMXCHHSC-FYSMJZIKSA-N n-[(4ar,7ar)-6-[5-fluoro-4-(2-hydroxypropan-2-yl)pyrimidin-2-yl]-7a-pyrazin-2-yl-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-2-yl]benzamide Chemical compound C1=C(F)C(C(C)(O)C)=NC(N2C[C@@]3(N=C(NC(=O)C=4C=CC=CC=4)SC[C@@H]3C2)C=2N=CC=NC=2)=N1 ACXSUNGMXCHHSC-FYSMJZIKSA-N 0.000 description 3
- XKQFXGMTUDTCDC-GUYCJALGSA-N n-[(4ar,7ar)-7a-pyrazin-2-yl-4a,5,6,7-tetrahydro-4h-pyrrolo[3,4-d][1,3]thiazin-2-yl]benzamide Chemical compound C1([C@@]23N=C(SC[C@@H]2CNC3)NC(=O)C=2C=CC=CC=2)=CN=CC=N1 XKQFXGMTUDTCDC-GUYCJALGSA-N 0.000 description 3
- HEIXGBWBMDOTLZ-UHFFFAOYSA-N n-[5-(5-fluoropyrimidin-2-yl)-6a-pyridin-3-yl-3,3a,4,6-tetrahydropyrrolo[3,4-c][1,2]oxazole-1-carbothioyl]benzamide Chemical compound N1=CC(F)=CN=C1N1CC2(C=3C=NC=CC=3)N(C(=S)NC(=O)C=3C=CC=CC=3)OCC2C1 HEIXGBWBMDOTLZ-UHFFFAOYSA-N 0.000 description 3
- VMSLAKZLWGYLIY-UHFFFAOYSA-N n-[6-(5-fluoropyrimidin-2-yl)-7a-pyridin-3-yl-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-2-yl]benzamide Chemical compound N1=CC(F)=CN=C1N1CC2(C=3C=NC=CC=3)N=C(NC(=O)C=3C=CC=CC=3)SCC2C1 VMSLAKZLWGYLIY-UHFFFAOYSA-N 0.000 description 3
- FURKQSBFHDEDDH-UHFFFAOYSA-N n-[[1-(5-fluoro-4-methoxy-6-methylpyrimidin-2-yl)-4-(hydroxymethyl)-3-pyrazin-2-ylpyrrolidin-3-yl]carbamothioyl]benzamide Chemical compound CC1=C(F)C(OC)=NC(N2CC(C(CO)C2)(NC(=S)NC(=O)C=2C=CC=CC=2)C=2N=CC=NC=2)=N1 FURKQSBFHDEDDH-UHFFFAOYSA-N 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- BXKDNJRLVZGLQS-UHFFFAOYSA-N tert-butyl 2-benzamido-7a-pyrazin-2-yl-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazine-6-carboxylate Chemical compound N=1C2(C=3N=CC=NC=3)CN(C(=O)OC(C)(C)C)CC2CSC=1NC(=O)C1=CC=CC=C1 BXKDNJRLVZGLQS-UHFFFAOYSA-N 0.000 description 3
- VGKYBZPZSRDNTE-UHFFFAOYSA-N tert-butyl n-[2-[methoxy(methyl)amino]-2-oxoethyl]-n-prop-2-enylcarbamate Chemical compound CON(C)C(=O)CN(CC=C)C(=O)OC(C)(C)C VGKYBZPZSRDNTE-UHFFFAOYSA-N 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000009261 transgenic effect Effects 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- YUHZIUAREWNXJT-UHFFFAOYSA-N (2-fluoropyridin-3-yl)boronic acid Chemical class OB(O)C1=CC=CN=C1F YUHZIUAREWNXJT-UHFFFAOYSA-N 0.000 description 2
- ZNGBNHKJLFAUIF-XPTSAGLGSA-N (4aR,7aR)-6-(5-fluoropyrimidin-2-yl)-7a-pyrazin-2-yl-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-2-amine Chemical compound NC1=N[C@]2(CN(C[C@H]2CS1)c1ncc(F)cn1)c1cnccn1 ZNGBNHKJLFAUIF-XPTSAGLGSA-N 0.000 description 2
- CNBQWOXMXVVDBZ-QFYYESIMSA-N (4ar,7ar)-6-(5-fluoro-4-methoxy-6-methylpyrimidin-2-yl)-7a-pyrazin-2-yl-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-2-amine Chemical compound CC1=C(F)C(OC)=NC(N2C[C@@]3(N=C(N)SC[C@@H]3C2)C=2N=CC=NC=2)=N1 CNBQWOXMXVVDBZ-QFYYESIMSA-N 0.000 description 2
- IPKZSHARAVFRGW-BONVTDFDSA-N (4ar,7ar)-6-(5-fluoropyrimidin-2-yl)-7a-pyridin-2-yl-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-2-amine Chemical compound C([C@@]1(N=C(SC[C@@H]1C1)N)C=2N=CC=CC=2)N1C1=NC=C(F)C=N1 IPKZSHARAVFRGW-BONVTDFDSA-N 0.000 description 2
- SRNJLGMFMGFYMR-SCLBCKFNSA-N (4ar,7as)-6-(5-fluoro-4-propan-2-ylpyrimidin-2-yl)-7a-pyridin-3-yl-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-2-amine Chemical compound C1=C(F)C(C(C)C)=NC(N2C[C@@]3(N=C(N)SC[C@@H]3C2)C=2C=NC=CC=2)=N1 SRNJLGMFMGFYMR-SCLBCKFNSA-N 0.000 description 2
- BTDOCELRFCOJIJ-XHDPSFHLSA-N (4ar,7as)-6-(5-fluoropyrimidin-2-yl)-7a-pyridin-3-yl-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-2-amine Chemical compound C([C@@]1(N=C(SC[C@@H]1C1)N)C=2C=NC=CC=2)N1C1=NC=C(F)C=N1 BTDOCELRFCOJIJ-XHDPSFHLSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 2
- GJEHRQMKOHWFGH-ZXFYNJNUSA-N 2-[2-[(4ar,7ar)-2-amino-7a-pyrazin-2-yl-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-6-yl]-5-fluoropyrimidin-4-yl]propan-2-ol;hydrochloride Chemical compound Cl.C1=C(F)C(C(C)(O)C)=NC(N2C[C@@]3(N=C(N)SC[C@@H]3C2)C=2N=CC=NC=2)=N1 GJEHRQMKOHWFGH-ZXFYNJNUSA-N 0.000 description 2
- PUWPLAOZXPBDEI-KPZWWZAWSA-N 2-[2-[(4ar,7as)-2-amino-7a-pyridin-3-yl-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-6-yl]-5-fluoropyrimidin-4-yl]propan-2-ol Chemical compound C1=C(F)C(C(C)(O)C)=NC(N2C[C@@]3(N=C(N)SC[C@@H]3C2)C=2C=NC=CC=2)=N1 PUWPLAOZXPBDEI-KPZWWZAWSA-N 0.000 description 2
- DBZAKQWXICEWNW-UHFFFAOYSA-N 2-acetylpyrazine Chemical compound CC(=O)C1=CN=CC=N1 DBZAKQWXICEWNW-UHFFFAOYSA-N 0.000 description 2
- NBCBXZRKUNIAMQ-UHFFFAOYSA-N 2-bromo-1-pyrazin-2-ylethanone;hydrobromide Chemical compound Br.BrCC(=O)C1=CN=CC=N1 NBCBXZRKUNIAMQ-UHFFFAOYSA-N 0.000 description 2
- RGALBQILADNMKA-UHFFFAOYSA-N 2-bromo-1-pyridin-4-ylethanone;hydron;bromide Chemical compound Br.BrCC(=O)C1=CC=NC=C1 RGALBQILADNMKA-UHFFFAOYSA-N 0.000 description 2
- UODINHBLNPPDPD-UHFFFAOYSA-N 2-bromo-5-fluoropyridine Chemical compound FC1=CC=C(Br)N=C1 UODINHBLNPPDPD-UHFFFAOYSA-N 0.000 description 2
- OBZDPELYPGXTMH-UHFFFAOYSA-N 2-chloro-5-fluoro-4-(2-fluoropropan-2-yl)pyrimidine Chemical compound CC(C)(F)C1=NC(Cl)=NC=C1F OBZDPELYPGXTMH-UHFFFAOYSA-N 0.000 description 2
- OERSDRQKVAOYKN-UHFFFAOYSA-N 2-chloro-5-fluoro-4-propan-2-ylpyrimidine Chemical compound CC(C)C1=NC(Cl)=NC=C1F OERSDRQKVAOYKN-UHFFFAOYSA-N 0.000 description 2
- AGYUQBNABXVWMS-UHFFFAOYSA-N 2-chloro-5-fluoropyrimidine Chemical compound FC1=CN=C(Cl)N=C1 AGYUQBNABXVWMS-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- WEGYGNROSJDEIW-UHFFFAOYSA-N 3-Acetylpyridine Chemical compound CC(=O)C1=CC=CN=C1 WEGYGNROSJDEIW-UHFFFAOYSA-N 0.000 description 2
- DOCOILJQTWNPDU-UHFFFAOYSA-N 5-(5-fluoro-4-methoxy-6-methylpyrimidin-2-yl)-6a-pyrazin-2-yl-3,3a,4,6-tetrahydro-1h-pyrrolo[3,4-c][1,2]oxazole Chemical compound CC1=C(F)C(OC)=NC(N2CC3(NOCC3C2)C=2N=CC=NC=2)=N1 DOCOILJQTWNPDU-UHFFFAOYSA-N 0.000 description 2
- OHYPPEKJCAOOCH-UHFFFAOYSA-N 5-(5-fluoropyrimidin-2-yl)-1-[(4-methoxyphenyl)methyl]-6a-pyridin-3-yl-3,3a,4,6-tetrahydropyrrolo[3,4-c][1,2]oxazole Chemical compound C1=CC(OC)=CC=C1CN1C2(C=3C=NC=CC=3)CN(C=3N=CC(F)=CN=3)CC2CO1 OHYPPEKJCAOOCH-UHFFFAOYSA-N 0.000 description 2
- LPXJQMGAKQBEDL-UHFFFAOYSA-N 5-(5-fluoropyrimidin-2-yl)-6a-pyridin-3-yl-3,3a,4,6-tetrahydro-1h-pyrrolo[3,4-c][1,2]oxazole Chemical compound N1=CC(F)=CN=C1N1CC2(C=3C=NC=CC=3)NOCC2C1 LPXJQMGAKQBEDL-UHFFFAOYSA-N 0.000 description 2
- DSDKBBVBHYSGEM-UHFFFAOYSA-N 6a-pyridin-3-yl-1,3,3a,4,5,6-hexahydropyrrolo[3,4-c][1,2]oxazole Chemical compound N1OCC2CNCC21C1=CC=CN=C1 DSDKBBVBHYSGEM-UHFFFAOYSA-N 0.000 description 2
- UWFQBNYXHRMJPO-UHFFFAOYSA-N 6a-pyridin-4-yl-1,3,3a,4,5,6-hexahydropyrrolo[3,4-c][1,2]oxazole Chemical compound N1OCC2CNCC21C1=CC=NC=C1 UWFQBNYXHRMJPO-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- 239000007868 Raney catalyst Substances 0.000 description 2
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 2
- 229910000564 Raney nickel Inorganic materials 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- DZJXKISLUDYJSV-UHFFFAOYSA-N [N].C1CCNC1 Chemical compound [N].C1CCNC1 DZJXKISLUDYJSV-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 150000002440 hydroxy compounds Chemical class 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- JDAZHYOKEJTPKU-UHFFFAOYSA-N n-[6-(5-fluoro-4-methoxy-6-methylpyrimidin-2-yl)-7a-pyrazin-2-yl-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-2-yl]benzamide Chemical compound CC1=C(F)C(OC)=NC(N2CC3(N=C(NC(=O)C=4C=CC=CC=4)SCC3C2)C=2N=CC=NC=2)=N1 JDAZHYOKEJTPKU-UHFFFAOYSA-N 0.000 description 2
- JTTOOJPKXZVRNA-UHFFFAOYSA-N n-[6-(5-fluoropyrimidin-2-yl)-7a-pyridin-2-yl-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-2-yl]benzamide Chemical compound N1=CC(F)=CN=C1N1CC2(C=3N=CC=CC=3)N=C(NC(=O)C=3C=CC=CC=3)SCC2C1 JTTOOJPKXZVRNA-UHFFFAOYSA-N 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 239000012454 non-polar solvent Substances 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 239000003880 polar aprotic solvent Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- JTCRYWOOQPACKY-HJPURHCSSA-N tert-butyl (4aR,7aR)-2-benzamido-7a-(5-fluoropyridin-2-yl)-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazine-6-carboxylate Chemical compound CC(C)(C)OC(=O)N1C[C@H]2CSC(NC(=O)c3ccccc3)=N[C@]2(C1)c1ccc(F)cn1 JTCRYWOOQPACKY-HJPURHCSSA-N 0.000 description 2
- RNPCMDOZIVRRIX-FDDCHVKYSA-N tert-butyl (4ar,7as)-2-benzamido-7a-pyridin-3-yl-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazine-6-carboxylate Chemical compound C([C@@H]1CN(C[C@@]1(N=1)C=2C=NC=CC=2)C(=O)OC(C)(C)C)SC=1NC(=O)C1=CC=CC=C1 RNPCMDOZIVRRIX-FDDCHVKYSA-N 0.000 description 2
- VAIFMGFIPXPELS-UHFFFAOYSA-N tert-butyl n-[2-(5-fluoropyridin-2-yl)-2-oxoethyl]-n-prop-2-enylcarbamate Chemical compound CC(C)(C)OC(=O)N(CC=C)CC(=O)C1=CC=C(F)C=N1 VAIFMGFIPXPELS-UHFFFAOYSA-N 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- MEFRYHOZPXPLCB-GTNSWQLSSA-N (4ar,7ar)-6-(5-fluoro-4-propan-2-ylpyrimidin-2-yl)-7a-pyrazin-2-yl-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-2-amine Chemical compound C1=C(F)C(C(C)C)=NC(N2C[C@@]3(N=C(N)SC[C@@H]3C2)C=2N=CC=NC=2)=N1 MEFRYHOZPXPLCB-GTNSWQLSSA-N 0.000 description 1
- DTSXRPVFPZNJMS-VFZGTOFNSA-N (4ar,7ar)-7a-(5-fluoropyridin-2-yl)-6-(5-fluoropyrimidin-2-yl)-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-2-amine Chemical compound C([C@@]1(N=C(SC[C@@H]1C1)N)C=2N=CC(F)=CC=2)N1C1=NC=C(F)C=N1 DTSXRPVFPZNJMS-VFZGTOFNSA-N 0.000 description 1
- WTVYSTMETNECED-XHDPSFHLSA-N (4ar,7as)-6-(5-fluoropyrimidin-2-yl)-7a-pyridin-4-yl-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-2-amine Chemical compound C([C@@]1(N=C(SC[C@@H]1C1)N)C=2C=CN=CC=2)N1C1=NC=C(F)C=N1 WTVYSTMETNECED-XHDPSFHLSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 1
- MOHYOXXOKFQHDC-UHFFFAOYSA-N 1-(chloromethyl)-4-methoxybenzene Chemical compound COC1=CC=C(CCl)C=C1 MOHYOXXOKFQHDC-UHFFFAOYSA-N 0.000 description 1
- RLRBAMDAFZZWMM-UHFFFAOYSA-N 1-ethoxyethenyl(trimethyl)stannane Chemical compound CCOC(=C)[Sn](C)(C)C RLRBAMDAFZZWMM-UHFFFAOYSA-N 0.000 description 1
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 1
- WMQUKDQWMMOHSA-UHFFFAOYSA-N 1-pyridin-4-ylethanone Chemical compound CC(=O)C1=CC=NC=C1 WMQUKDQWMMOHSA-UHFFFAOYSA-N 0.000 description 1
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 1
- IYGLMCCNOPCDCR-UHFFFAOYSA-N 2,4-dichloro-5-fluoro-6-methylpyrimidine Chemical compound CC1=NC(Cl)=NC(Cl)=C1F IYGLMCCNOPCDCR-UHFFFAOYSA-N 0.000 description 1
- WHPFEQUEHBULBW-UHFFFAOYSA-N 2,4-dichloro-5-fluoropyrimidine Chemical compound FC1=CN=C(Cl)N=C1Cl WHPFEQUEHBULBW-UHFFFAOYSA-N 0.000 description 1
- BDKLKNJTMLIAFE-UHFFFAOYSA-N 2-(3-fluorophenyl)-1,3-oxazole-4-carbaldehyde Chemical compound FC1=CC=CC(C=2OC=C(C=O)N=2)=C1 BDKLKNJTMLIAFE-UHFFFAOYSA-N 0.000 description 1
- AJKVQEKCUACUMD-UHFFFAOYSA-N 2-Acetylpyridine Chemical compound CC(=O)C1=CC=CC=N1 AJKVQEKCUACUMD-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- VNTNANCAPVJRJP-UHFFFAOYSA-N 3,4-dihydrothiazin-2-amine Chemical class NN1CCC=CS1 VNTNANCAPVJRJP-UHFFFAOYSA-N 0.000 description 1
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- CNBQWOXMXVVDBZ-UHFFFAOYSA-N 6-(5-fluoro-4-methoxy-6-methylpyrimidin-2-yl)-7a-pyrazin-2-yl-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-2-amine Chemical compound CC1=C(F)C(OC)=NC(N2CC3(N=C(N)SCC3C2)C=2N=CC=NC=2)=N1 CNBQWOXMXVVDBZ-UHFFFAOYSA-N 0.000 description 1
- MEFRYHOZPXPLCB-UHFFFAOYSA-N 6-(5-fluoro-4-propan-2-ylpyrimidin-2-yl)-7a-pyrazin-2-yl-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-2-amine Chemical compound C1=C(F)C(C(C)C)=NC(N2CC3(N=C(N)SCC3C2)C=2N=CC=NC=2)=N1 MEFRYHOZPXPLCB-UHFFFAOYSA-N 0.000 description 1
- SRNJLGMFMGFYMR-UHFFFAOYSA-N 6-(5-fluoro-4-propan-2-ylpyrimidin-2-yl)-7a-pyridin-3-yl-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-2-amine Chemical compound C1=C(F)C(C(C)C)=NC(N2CC3(N=C(N)SCC3C2)C=2C=NC=CC=2)=N1 SRNJLGMFMGFYMR-UHFFFAOYSA-N 0.000 description 1
- ZNGBNHKJLFAUIF-UHFFFAOYSA-N 6-(5-fluoropyrimidin-2-yl)-7a-pyrazin-2-yl-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-2-amine Chemical compound C1C2CSC(N)=NC2(C=2N=CC=NC=2)CN1C1=NC=C(F)C=N1 ZNGBNHKJLFAUIF-UHFFFAOYSA-N 0.000 description 1
- WTVYSTMETNECED-UHFFFAOYSA-N 6-(5-fluoropyrimidin-2-yl)-7a-pyridin-4-yl-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-2-amine Chemical compound C1C2CSC(N)=NC2(C=2C=CN=CC=2)CN1C1=NC=C(F)C=N1 WTVYSTMETNECED-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- DTSXRPVFPZNJMS-UHFFFAOYSA-N 7a-(5-fluoropyridin-2-yl)-6-(5-fluoropyrimidin-2-yl)-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-2-amine Chemical compound C1C2CSC(N)=NC2(C=2N=CC(F)=CC=2)CN1C1=NC=C(F)C=N1 DTSXRPVFPZNJMS-UHFFFAOYSA-N 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 239000012583 B-27 Supplement Substances 0.000 description 1
- 229940126077 BACE inhibitor Drugs 0.000 description 1
- PCBZRNYXXCIELG-WYFCWLEVSA-N COC1=CC=C(C[C@H](NC(=O)OC2CCCC3(C2)OOC2(O3)C3CC4CC(C3)CC2C4)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)N2C=NC3=C2N=CN=C3N(C)C)C=C1 Chemical compound COC1=CC=C(C[C@H](NC(=O)OC2CCCC3(C2)OOC2(O3)C3CC4CC(C3)CC2C4)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)N2C=NC3=C2N=CN=C3N(C)C)C=C1 PCBZRNYXXCIELG-WYFCWLEVSA-N 0.000 description 1
- 101100454807 Caenorhabditis elegans lgg-1 gene Proteins 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 241001137251 Corvidae Species 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 208000031124 Dementia Alzheimer type Diseases 0.000 description 1
- 239000007818 Grignard reagent Substances 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 238000010640 amide synthesis reaction Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- LURYMYITPCOQAU-UHFFFAOYSA-N benzoyl isocyanate Chemical compound O=C=NC(=O)C1=CC=CC=C1 LURYMYITPCOQAU-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940124301 concurrent medication Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000003618 cortical neuron Anatomy 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000002027 dichloromethane extract Substances 0.000 description 1
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- MJJALKDDGIKVBE-UHFFFAOYSA-N ebastine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)CCCN1CCC(OC(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 MJJALKDDGIKVBE-UHFFFAOYSA-N 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- FCZCIXQGZOUIDN-UHFFFAOYSA-N ethyl 2-diethoxyphosphinothioyloxyacetate Chemical compound CCOC(=O)COP(=S)(OCC)OCC FCZCIXQGZOUIDN-UHFFFAOYSA-N 0.000 description 1
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- RGZRSLKIOCHTSI-UHFFFAOYSA-N hydron;n-methylhydroxylamine;chloride Chemical compound Cl.CNO RGZRSLKIOCHTSI-UHFFFAOYSA-N 0.000 description 1
- XNXVOSBNFZWHBV-UHFFFAOYSA-N hydron;o-methylhydroxylamine;chloride Chemical compound Cl.CON XNXVOSBNFZWHBV-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000010952 in-situ formation Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- JNODQFNWMXFMEV-UHFFFAOYSA-N latrepirdine Chemical compound C1N(C)CCC2=C1C1=CC(C)=CC=C1N2CCC1=CC=C(C)N=C1 JNODQFNWMXFMEV-UHFFFAOYSA-N 0.000 description 1
- IXHBTMCLRNMKHZ-LBPRGKRZSA-N levobunolol Chemical compound O=C1CCCC2=C1C=CC=C2OC[C@@H](O)CNC(C)(C)C IXHBTMCLRNMKHZ-LBPRGKRZSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- VDCLSGXZVUDARN-UHFFFAOYSA-N molecular bromine;pyridine;hydrobromide Chemical compound Br.BrBr.C1=CC=NC=C1 VDCLSGXZVUDARN-UHFFFAOYSA-N 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- FFCSRGQHUAIVHV-UHFFFAOYSA-N n-[[1-(5-fluoropyrimidin-2-yl)-4-(hydroxymethyl)-3-pyridin-3-ylpyrrolidin-3-yl]carbamothioyl]benzamide Chemical compound OCC1CN(C=2N=CC(F)=CN=2)CC1(C=1C=NC=CC=1)NC(=S)NC(=O)C1=CC=CC=C1 FFCSRGQHUAIVHV-UHFFFAOYSA-N 0.000 description 1
- DYUWTXWIYMHBQS-UHFFFAOYSA-N n-prop-2-enylprop-2-en-1-amine Chemical compound C=CCNCC=C DYUWTXWIYMHBQS-UHFFFAOYSA-N 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 231100000189 neurotoxic Toxicity 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 238000007339 nucleophilic aromatic substitution reaction Methods 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 125000001979 organolithium group Chemical group 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- QJPQVXSHYBGQGM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 QJPQVXSHYBGQGM-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 235000015108 pies Nutrition 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000010956 selective crystallization Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 229940087562 sodium acetate trihydrate Drugs 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical class [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000007617 synaptic impairment Effects 0.000 description 1
- BXKDNJRLVZGLQS-AOMKIAJQSA-N tert-butyl (4ar,7ar)-2-benzamido-7a-pyrazin-2-yl-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazine-6-carboxylate Chemical compound C([C@@H]1CN(C[C@@]1(N=1)C=2N=CC=NC=2)C(=O)OC(C)(C)C)SC=1NC(=O)C1=CC=CC=C1 BXKDNJRLVZGLQS-AOMKIAJQSA-N 0.000 description 1
- RNPCMDOZIVRRIX-UHFFFAOYSA-N tert-butyl 2-benzamido-7a-pyridin-3-yl-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazine-6-carboxylate Chemical compound N=1C2(C=3C=NC=CC=3)CN(C(=O)OC(C)(C)C)CC2CSC=1NC(=O)C1=CC=CC=C1 RNPCMDOZIVRRIX-UHFFFAOYSA-N 0.000 description 1
- WADGHWKXQZVKFK-UHFFFAOYSA-N thiazin-2-amine Chemical compound NN1SC=CC=C1 WADGHWKXQZVKFK-UHFFFAOYSA-N 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261718728P | 2012-10-26 | 2012-10-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE031764T2 true HUE031764T2 (en) | 2017-07-28 |
Family
ID=49515508
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE13785730A HUE031764T2 (en) | 2012-10-26 | 2013-10-17 | Tetrahydropyrrolothiazine derivatives as BACE inhibitors |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9328124B2 (enExample) |
| EP (1) | EP2912041B1 (enExample) |
| JP (1) | JP6243921B2 (enExample) |
| CN (1) | CN104755484B (enExample) |
| CA (1) | CA2886507C (enExample) |
| CY (1) | CY1118623T1 (enExample) |
| DK (1) | DK2912041T3 (enExample) |
| ES (1) | ES2616835T3 (enExample) |
| HR (1) | HRP20170025T1 (enExample) |
| HU (1) | HUE031764T2 (enExample) |
| LT (1) | LT2912041T (enExample) |
| ME (1) | ME02576B (enExample) |
| PL (1) | PL2912041T3 (enExample) |
| PT (1) | PT2912041T (enExample) |
| RS (1) | RS55561B1 (enExample) |
| SI (1) | SI2912041T1 (enExample) |
| WO (1) | WO2014066132A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014223334C1 (en) | 2013-03-01 | 2018-10-18 | Amgen Inc. | Perfluorinated 5,6-dihydro-4H-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
| EA201591614A1 (ru) | 2013-03-08 | 2015-12-30 | Эмджен Инк. | Соединения 1,3-оксазин-2-амина, конденсированные с перфторированным циклопропилом, в качестве ингибиторов бета-секретазы и способы их применения |
| TWI684452B (zh) * | 2014-03-14 | 2020-02-11 | 美國禮來大藥廠 | 胺基噻嗪化合物 |
| CN106795147B (zh) | 2014-08-08 | 2020-09-22 | 美国安进公司 | 作为β-分泌酶抑制剂的环丙基稠合噻嗪-2-胺化合物和使用方法 |
| US10246429B2 (en) | 2015-08-06 | 2019-04-02 | Amgen Inc. | Vinyl fluoride cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use |
| US11548903B2 (en) | 2016-12-15 | 2023-01-10 | Amgen Inc. | Bicyclic thiazine and oxazine derivatives as beta-secretase inhibitors and methods of use |
| US10947223B2 (en) | 2016-12-15 | 2021-03-16 | Amgen Inc. | Substituted oxazines as beta-secretase inhibitors |
| WO2018112086A1 (en) | 2016-12-15 | 2018-06-21 | Amgen Inc. | Cyclopropyl fused thiazine derivatives as beta-secretase inhibitors and methods of use |
| CA3047288A1 (en) | 2016-12-15 | 2018-06-21 | Amgen Inc. | Thiazine derivatives as beta-secretase inhibitors and methods of use |
| MA50007A (fr) | 2016-12-15 | 2021-04-07 | Amgen Inc | Dérivés de dioxyde de 1,4-thiazine et de dioxyde de 1,2,4-thiadiazine en tant qu'inhibiteurs de bêta-sécrétase et procédés d'utilisation |
| CN106632001A (zh) * | 2016-12-28 | 2017-05-10 | 山东诚汇双达药业有限公司 | 一种4‑（溴乙酰基）吡啶氢溴酸盐的制备方法 |
| CN110452179A (zh) * | 2019-06-25 | 2019-11-15 | 南京普锐达医药科技有限公司 | 一种2-氯-4-甲氧基-5-氰基嘧啶的合成方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2609582A1 (en) * | 2005-06-14 | 2006-12-28 | Schering Corporation | Aspartyl protease inhibitors |
| EP2151435A4 (en) | 2007-04-24 | 2011-09-14 | Shionogi & Co | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE |
| US20100317850A1 (en) | 2008-01-18 | 2010-12-16 | Yuichi Suzuki | Condensed aminodihydrothiazine derivative |
| EA201001532A1 (ru) | 2008-04-22 | 2011-06-30 | Шеринг Корпорейшн | Соединения фенилзамещенного 2-имино-3-метилпирролопиримидинона в качестве ингибиторов bace-1, композиции и их применение |
| KR101324426B1 (ko) | 2008-06-13 | 2013-10-31 | 시오노기세야쿠 가부시키가이샤 | β 세크레타제 저해 작용을 갖는 황 함유 복소환 유도체 |
| ES2539859T3 (es) | 2008-09-30 | 2015-07-06 | Eisai R&D Management Co., Ltd. | Nuevo derivado de aminodihidrotiazina condensado |
| AR077277A1 (es) * | 2009-07-09 | 2011-08-17 | Lilly Co Eli | Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer |
| GB0912778D0 (en) * | 2009-07-22 | 2009-08-26 | Eisai London Res Lab Ltd | Fused aminodihydro-oxazine derivatives |
| EP2511269A4 (en) * | 2009-12-11 | 2013-04-24 | Shionogi & Co | FUSED HETEROCYCLIC COMPOUND HAVING AN AMINO GROUP |
| GB201100181D0 (en) | 2011-01-06 | 2011-02-23 | Eisai Ltd | Fused aminodihydrothiazine derivatives |
| US8598161B2 (en) | 2011-05-24 | 2013-12-03 | Bristol-Myers Squibb Company | Compounds for the reduction of beta-amyloid production |
| JO3143B1 (ar) | 2012-04-03 | 2017-09-20 | Lilly Co Eli | مركبات تتراهيدرو بيرولو ثيازين |
| GB201212871D0 (en) * | 2012-07-20 | 2012-09-05 | Eisai Ltd | Novel compounds |
| TWI593692B (zh) | 2013-03-12 | 2017-08-01 | 美國禮來大藥廠 | 四氫吡咯并噻嗪化合物 |
-
2013
- 2013-10-17 SI SI201330463T patent/SI2912041T1/sl unknown
- 2013-10-17 HU HUE13785730A patent/HUE031764T2/en unknown
- 2013-10-17 CN CN201380055699.5A patent/CN104755484B/zh not_active Expired - Fee Related
- 2013-10-17 RS RS20170016A patent/RS55561B1/sr unknown
- 2013-10-17 DK DK13785730.6T patent/DK2912041T3/en active
- 2013-10-17 CA CA2886507A patent/CA2886507C/en not_active Expired - Fee Related
- 2013-10-17 ES ES13785730.6T patent/ES2616835T3/es active Active
- 2013-10-17 PT PT137857306T patent/PT2912041T/pt unknown
- 2013-10-17 LT LTEP13785730.6T patent/LT2912041T/lt unknown
- 2013-10-17 EP EP13785730.6A patent/EP2912041B1/en active Active
- 2013-10-17 US US14/427,648 patent/US9328124B2/en not_active Expired - Fee Related
- 2013-10-17 PL PL13785730T patent/PL2912041T3/pl unknown
- 2013-10-17 JP JP2015539666A patent/JP6243921B2/ja not_active Expired - Fee Related
- 2013-10-17 HR HRP20170025TT patent/HRP20170025T1/hr unknown
- 2013-10-17 WO PCT/US2013/065418 patent/WO2014066132A1/en not_active Ceased
-
2017
- 2017-02-10 ME MEP-2017-4A patent/ME02576B/me unknown
- 2017-02-10 CY CY20171100191T patent/CY1118623T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2886507C (en) | 2016-09-20 |
| CA2886507A1 (en) | 2014-05-01 |
| JP2015535247A (ja) | 2015-12-10 |
| SI2912041T1 (sl) | 2017-02-28 |
| US9328124B2 (en) | 2016-05-03 |
| CN104755484A (zh) | 2015-07-01 |
| LT2912041T (lt) | 2017-03-10 |
| EP2912041A1 (en) | 2015-09-02 |
| DK2912041T3 (en) | 2017-02-27 |
| ME02576B (me) | 2017-06-20 |
| US20150232483A1 (en) | 2015-08-20 |
| EP2912041B1 (en) | 2016-12-14 |
| HRP20170025T1 (hr) | 2017-03-10 |
| PT2912041T (pt) | 2017-02-13 |
| CN104755484B (zh) | 2016-02-17 |
| CY1118623T1 (el) | 2017-07-12 |
| ES2616835T3 (es) | 2017-06-14 |
| JP6243921B2 (ja) | 2017-12-06 |
| PL2912041T3 (pl) | 2017-06-30 |
| RS55561B1 (sr) | 2017-05-31 |
| WO2014066132A1 (en) | 2014-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2912041T3 (en) | TETRAHYDROPYRROLOTHIAZINE DERIVATIVES AS BACE INHIBITORS | |
| CA2898500C (en) | Tetrahydropyrrolothiazine compounds | |
| DK2836495T3 (en) | Tetrahydropyrrolothiazine compounds | |
| US9029367B2 (en) | BACE inhibitors | |
| CA2938616C (en) | Aminothiazine compounds | |
| US9828390B2 (en) | Tetrahydropyrrolo[3,4-D][1,3]thiazine-derivative as BACE inhibitor | |
| AU2014228351B2 (en) | Tetrahydropyrrolothiazine compounds | |
| HK1212694B (en) | Tetrahydropyrrolothiazine compounds |